Expressed prostatic secretions (EPS) are proximal fluids of the prostate that are increasingly being utilized as a clinical source for diagnostic and prognostic assays for prostate cancer (PCa). These fluids contain an abundant amount of microvesicles reflecting the secretory function of the prostate gland, and their protein composition remains poorly defined in relation to PCa. Using expressed prostatic secretions in urine (EPS-urine), exosome preparations were characterized by a shotgun proteomics procedure. In pooled EPS-urine exosome samples, ∼900 proteins were detected. Many of these have not been previously observed in the soluble proteome of EPS generated by our labs or other related exosome proteomes. We performed systematic comparisons of our data against previously published, prostate-related proteomes, and global annotation analyses to highlight functional processes within the proteome of EPS-urine derived exosomes. The acquired proteomic data have been deposited to the Tranche repository and will lay the foundation for more extensive investigations of PCa derived exosomes in the context of biomarker discovery and cancer biology.
fluid-derived sources [7] , other studies have shown that prostate-derived vesicles can be isolated from plasma [8] , urine [9] , human tissues [10] , and cell lines [11] . In the context of biomarker discovery, prostasomes derived from PCa patients likely contain a tumor-enriched repertoire of biomolecules (i.e. proteins, miRNAs, lipids, etc.) that could represent a novel and easily isolatable biomarker source. For this reason there is great interest in developing highthroughput strategies to isolate and characterize exosomes and related prostasomes from human bodily fluids [12] .
Expressed prostatic secretions in urine, EPS-urine, are collected in voided urine after digital rectal examination [13] . For EPS-urines, multiple genetic assays (PCA3, TM-PRSS2) for PCa diagnostics are being developed [14] , resulting in a recent FDA approval for the PCA3 commercial assay. EPS-urine contains both the exosome components found in urine, as well as prostasomes secreted from the prostate. For this study, we refer to both as EPS urine exosomes.
Our collaborative research group has recently published three proteomic studies characterizing EPS fluids associated with different stages of benign prostatic conditions and PCa [15] [16] [17] . Taking advantage of these previous studies and their associated proteomes, exosomes from EPS-urine samples were isolated by standard ultracentrifugation methods. Next generation ultra-performance liquid chromatographymass spectrometry-MS (UHPLC-MS) analysis was then performed across exosome pools isolated from low-grade PCa patients and noncancer controls. One emphasis was on the global annotation of this large resource of EPS urine-derived exosomes, as well as the systematic comparison to previously published data on prostatic secretions [15] [16] [17] and urinerelated exosomes [18] .
All samples were collected from patients after informed consent following Institutional Review Board-approved protocols at Urology of Virginia, Sentara Medical School, and the Eastern Virginia Medical School along with the Research Ethics Board of the University Health Network, as previously described [13] . Pools (2 mL/sample) of EPS-urines were derived from 12 patients classified as having low grade, Gleason 6, organ-confined PCa and 12 noncancer patients confirmed as biopsy negative for PCa. Each sample was selected for expression of prostate-specific antigen (PSA) in the fluids at >15 g/mL (Supporting Information Table 1 ). Exosomes were isolated by standard differential ultracentrifugation [19] with a DTT/sucrose wash step [12] , processed using 2,2,2trifluoroethanol and prepared for MS analyses as previously described [20] . Each sample was analyzed in duplicate using an UHPLC system on-line to a Q-Exactive mass spectrometer equipped with a nano-electrospray ion source. Raw data were analyzed using the MaxQuant platform [21] to obtain peptide/protein identification (FDR <1%). Functional annotation and comparisons to other published data was accomplished using the David bioinformatics resource [22] and the ProteinCenter software suite. See the Supporting Information Methods for detailed information.
The analysis workflow is summarized in Fig. 1A , and in total, close to 900 proteins were identified in the two EPSurine exosome pools, representing the most comprehensive data for this clinically relevant fluid to date (Supporting Information Table 2 ). These EPS-urine exosome protein lists were then compared to our previous analyses of prostatic secretions [15] [16] [17] to determine whether this fractionation step enriched for target proteins previously identified in the fluid studies, and whether novel vesicle-associated protein targets were identified. In addition, the generated EPS-urine exosome proteome was compared against a comprehensive healthy human urine exosome protein list [18] . This comparison could facilitate removal of exosomal proteins from the general urine background, hence enriching for prostasomal proteins within our data. First, we performed global GO analyses to obtain a general overview of enriched functional classes within the ∼900 EPS-urine exosome proteins. In Fig. 1B , we show representative categories of the most significantly enriched GO terms. Within the molecular function (GO: MF) category, the top enriched terms were related to proteolytic enzyme function, highlighting the importance of exosomes in extracellular matrix modulation. In the cellular component (GO: CC) category, the top terms were linked to extracellular matrix, plasma membrane, and endosomes, highlighting both the biogenesis and extracellular localization of exosomes. Interestingly, in the biological process (GO: BP) category, the top terms were involved in inflammation, defense response, and complement activation. Next, we compared our EPS-urine exosome proteome against proteomic data from direct-EPS [15, 16] and EPS-urines [17] that our groups have recently published (Fig. 1C ). As expected, a large overlap was found between these independent proteomics data, with prostate-enriched proteins such as PSA, prostatic acid phosphatase (ACPP), prostate transglutaminase (TGM4), and prostate-specific membrane antigen (PSMA) found consistently among all studies. The majority of currently used exosome markers were also found in common among all analyzed proteomics data and included: membrane surface markers (CD9, CD63, CD81), programmed cell death 6-interacting protein (Alix), annexin-2 and 5 (ANXA2/5), and tumor susceptibility gene 101 (TSG101). This evidence suggests that, proteins found in urine exosome preparations are relatively abundant and thus also detected when the whole fluid is analyzed, or alternatively, some of these proteins could also exist as a soluble form. On the other hand, flotillin-1/2 was only detected in the enriched exosome samples, highlighting that exosome enrichment does indeed enrich for a different overall proteome.
Our second comparison was based on a recently published proteomic study of exosome proteins isolated from healthy human urine samples [18] (Fig. 2) . The majority of proteins identified in the EPS-urine exosomes were in common with this extensive database of urine exosome proteins. Similar to our comparison above, all exosomal markers (CD9, CD63, CD81, Alix, TSG101, FLOT1, FLOT2, ANXA2, ANXA5) and prostate-enriched proteins (PSA, ACPP, TGM4, PSMA) were found in both datasets. Since both datasets were recorded on different MS platforms, direct quantitative comparisons are not possible. We therefore focused on identifying proteins exclusively detected in the EPS-urine exosomes (127 proteins in Fig. 2 ) that could represent proteins unique to prostasome-derived proteins present in prostatic secretions. Global GO enrichment analyses of these 127 proteins revealed that the most significant functional categories were related to inflammation: immune response (27 proteins), response to wounding (21 proteins), defense response (19 proteins), inflammatory response (14 proteins), and complement activation (7 proteins; Fig. 1B ). Since our exosome isolation protocol was virtually identical to the study on healthy urinederived exosomes by Wang et al. [18] it is reasonable to conclude that the majority of inflammatory proteins detected in our study arise from the prostatic secretion component of Figure 2 . Comparison of the current study to a previously published urine exosome proteome from healthy donors [18] .
EPS urine with a likely link to PCa [23] . Alternatively, it is possible that immune-related proteins such as complement factors and immunoglobulins are derived from immune cells or blood present in these complex clinical fluids. Certainly the presence of highly abundant contaminating proteins, in exosome preparations from cancer-related biofluids such as EPSurine, must be taken into account and further verified before generalizing their presence to a clinical association with the cancerous condition. This potential caveat will require more sophisticated isolation procedures in the future.
There is a long history of prostate-associated microvesicle research, stemming largely from the definition of prostasome structure and physiologic functions [5] . Defining how the proteins and other molecules in prostasomes are altered or contribute to benign and PCa disease in older men has been an important research question [24] . More recently, there has been an increase in prostate-related microvesicle research and their protein content, and this corresponds to continued improvement in MS-based applications. In this paper, we thought to take the first step in defining the target proteins associated with exosomes isolated from proximal fluids of the prostate. The readily obtained EPS-urine samples that are used in current PCA3 diagnostic tests in PCa patients are an ideal fluid for future exosome-based investigations as they are already being collected for clinical applications. Exosomes derived from EPS-urines can be used to detect PCA3 and TM-PRSS2:ERG mRNA [9] . The goal of the current study was to define the exosome proteome from EPS fluids using the latest generation of LC-MS equipment. Virtually all currently used exosome markers and prostate-enriched proteins were readily detectable using this technology. Comparison to previously published proteomics data using direct-EPS and EPS-urines without enrichment for exosomes highlighted that significant number of additional proteins were identified. Similar results were obtained by comparison to a large resource of healthy male urine derived exosomes, highlighting the potential contribution of prostatic secretions and inflammatory components. Potential advantages of exosome isolation from EPS-urines, as compared to an analysis of the "whole" EPS-urine (which also contains exosomes) are based on the well-known heterogeneity of clinically obtained urine samples and the broad dynamic concentration ranges of proteins in these fluids. Using an exosome enrichment step could be a way to better define protein targets and standardize the comparison of samples obtained from many individuals [12] . An additional advantage would be the analyses of other cargo molecules within EPS-urine derived exosomes such as mRNA and miRNA. Defining the protein components that are unique to the prostate-specific prostasomal vesicles in EPS-urine exosomes facilitates design of specific immunological or other affinity capture strategies.
In summary, we report the largest resource of exosomal proteins identified for EPS urines, to date. Using a combination of 2,2,2-trifluoroethanol-based protein extraction and heated column UHPLC-MS of pooled EPS-urines from controls and low-grade prostate cancer patients, almost 900 pro-teins were identified. Interestingly, these next-generation proteomics analyses strategies were sensitive enough to provide significant depth of detection from as little as 24 mL of unprocessed EPS-urine. Using this proteomics technology on larger EPS-urine cohorts and other prostatic secretions [15] [16] [17] , in combination with exosomal enrichment, represent powerful approaches for the identification of biomarkers for PCa. The current study will provide an important benchmark for such future investigations.
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